≥ tenantsThey Are Working with Us -New Companies at <strong>BB</strong> <strong>Centrum</strong>The <strong>BB</strong> <strong>Centrum</strong> complex is currently comprised of 15 completed buildings, whose totalarea covers almost 200,000 square metres. It is the home of dozens of domestic and foreigncompanies and is a locality where about 10,000 people have found employment. We are awarethat when a certain <strong>BB</strong> <strong>Centrum</strong> building fills up with people from a new company, many ofus often do not notice this change unless it occurs in our immediate proximity. This is why wewould like to introduce two of these companies in this column.Pioneer InvestmentsPioneer Investments Group is an assetmanagement division of one of the leadingbanking groups, UniCredit. It has been involvedin the industry for over 80 years, or since 1928,to be more precise, when Pioneer Fund, thethird oldest fund in the U.S.A, was established.With its main headquarters located in Milan,Italy, the Group is currently present in 22countries, including all the major worldmarkets. Pioneer Investments global assetmanagement portfolio currently exceeds €152billion (as of July 31, 2012).They have been operating in the CzechRepublic since 1995, providing services toindividual and institutional investors as wellFRESENIUS KABIThe end of last year saw the arrival of a new tenant at FILADELFIE: Fresenius Kabi, a daughtercompany of Fresenius SE Group. This company has been engaged – on a long-term basis – in thetreatment of critical conditions or chronic disease affected patients, regardless of whether theyare being treated in hospitals or as outpatients. Holding a leading position in the productionof infusion therapies and clinical nutrition products, they operate not only in Europe, but innumerous Latin American and Asian countries as well. The pharmaceutical company, FreseniusKabi, is headquartered on the 17th floor of Building FILADELFIE. In the offices, there arecurrently 32 employees responsible for meeting orders placed by hospitals and pharmacies aswell as logistics, the registration of remedies, bookkeeping, marketing and sale of medicinesdistributed in this country. Fresenius Kabi is a leading player in the production of infusion therapyand clinical nutrition products in Europe as well as many countries in Latin America and Asia.Moreover, they rank among the most influential suppliers of intravenous generics on the U.S.pharmaceutical market. The company has been engaged – on a long-term basis – in treatmentfor critical conditions or chronic diseases affecting patients both hospitalised or outpatient.Fresenius Kabi in Facts and FiguresGlobally, Fresenius Kabi Group have a staff of 24,000, a chain of sales organizations and over55 production facilities. In 2011, the company’s revenues exceeded €3.964 billion, with EBITat €803 million.Global PresenceThe network of subsidiaries and production facilities around the world is one of the majoradvantages of Fresenius Kabi Group. With corporate headquarters in Germany’s Bad Homburg,this Group possesses a large network of sales subsidiaries and production facilities in Europe,America, Africa and Australia.10
as foundations. The product line consists of the Czech family ofPioneer Funds, two foreign families of Pioneer Funds (registeredin Luxembourg), two funds designed for foundations, and regularinvestment funds (RYTMUS programme, and life cycle products:Rentier Invest and Zlatá rybka).Leaving their offices in the low-energy Danube House in Prague’sdistrict of Karlín, Pioneer Investments Group will move into the newoffice space in FILADELFIE at the end of September. This step ismeant to facilitate more effective communication within the UniCreditGroup, to which Pioneer Investments belong.The sister UniCredit Bank Czech Republic has already moved inand, based on their experience, the new building fulfils all theirrequirements, including easy transport access, quality supportingfacilities and the overall capacity, which is in line with the needs of thisdynamically growing financial group.